The role of apolipoprotein e in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis

Journal of Drug Targeting

Volumn 17, Issue 4, 2009, Pages 257-267

  Shubar, Hend M ^a   Dunay, Ildiko R ^a   Lachenmaier, Sabrina ^a   Dathe, Margitta ^b   Bushrab, Faris Nadiem ^c   Mauludin, Rachmat ^c   Mller, Rainer H ^c   Fitzner, Rudolf ^a   Borner, Klaus ^a   Liesenfeld, Oliver ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

ApoE; Atovaquone; Blood brain barrier; Brain; HPLC; Toxoplasmosis

Indexed keywords

APOLIPOPROTEIN E; ATOVAQUONE; POLOXAMER; POLOXAMER 184; POLYMER; POLYSORBATE 80; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; DRUG UPTAKE; ENCEPHALITIS; ENDOTHELIUM CELL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXOPLASMOSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; APOLIPOPROTEINS E; ATOVAQUONE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; COCULTURE TECHNIQUES; MICE; POLOXAMER; POLYSORBATES; RATS; RATS, WISTAR; SURFACE-ACTIVE AGENTS; TISSUE DISTRIBUTION; TOXOPLASMOSIS, ANIMAL; TOXOPLASMOSIS, CEREBRAL;

EID: 70749127103     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902718680     Document Type: Article

References (53)

1. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. (1995). Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 41, 44-48.
2. Araujo FG, Huskinson J, Remington JS. (1991). Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother, 35, 293-299.
3. Araujo FG, Suzuki Y, Remington JS. (1996). Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Eur J Clin Microbiol Infect Dis, 15, 394-397.
4. Baggish AL, Hill DR. (2002). Antiparasitic agent atovaquone. Antimicrob Agents Chemother, 46, 1163-1173.
5. Begley DJ. (1996). The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48, 136-146.
6. Begley DJ. (2004). Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther, 104, 29-45.
7. Blunk T, Hochstrasser DF, Sanchez JC, Muller BW, Muller RH. (1993). Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis, 14, 1382-1387.
8. Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer VV, et al. (1999). In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev, 36, 165-178.
9. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, et al. (2002). Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis, 34, 1243-1250.
10. Conley FK, Jenkins KA, Remington JS. (1981). Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol, 12, 690-698.
11. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, et al. (1992). Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med, 116, 33-43.
12. Dathe M, Keller S, Sauer I, Bienert M. (2007). Cellular uptake of liposomal and micellar carriers mediated by APOE-derived peptides. In: Langel U (Eds.), Handbook of Cell-Penetrating Peptides (2nd ed., pp. 484-500). Boca Raton, FL: CRC Press 481-501.
13. Dehouck B, Dehouck MP, Fruchart JC, Cecchelli R. (1994). Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol, 126, 465-473.
14. Deli MA, Abraham CS, Kataoka Y, Niwa M. (2005). Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol, 25, 59-127.
15. Deli MA, Dehouck MP, Abraham CS, Cecchelli R, Joo F. (1995). Penetration of small molecular weight substances through cultured bovine brain capillary endothelial cell monolayers: The early effects of cyclic adenosine 3?,5?-monophosphate. Exp Physiol, 80, 675-678.
16. Deli MA, Joo F, Krizbai I, Lengyel I, Nunzi MG, Wolff JR. (1993). Calcium/ calmodulin-stimulated protein kinase II is present in primary cultures of cerebral endothelial cells. J Neurochem, 60, 1960-1963.
17. Dunay IR, Heimesaat MM, Bushrab FN, Muller RH, Stocker H, et al. (2004). Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother, 48, 4848-4854.
18. Fernandez-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vilde JL. (1991). Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother, 35, 2049-2052.
19. Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, et al. (2001). Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci, 12, 215-222.
20. Hagberg L, Palmertz B, Lindberg J. (1993). Doxycycline and pyrimethamine for toxoplasmic encephalitis. Scand J Infect Dis, 25, 157-160.
21. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, et al. (1993). Comparison of atovaquone (566C80) with trimethoprimsulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med, 328, 1521-1527.
22. Hughes WT. (1995). The role of atovaquone tablets in treating Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol, 8, 247-252.
23. Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, et al. (2001). Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. Aids, 15, 583-589.
24. Kasper L. (Ed.) (1997). Toxoplasma infection (1197 pp.). New York: McGraw-Hill.
25. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. (1996a). Pyrimethamine-clindamycin vs. pyrimethaminesulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis, 22, 268-275. (Pubitemid 26056155)
26. Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. (1996b). Atovaquone as long-term suppressive therapy for toxoplasmicencephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Aids, 10, 1107-1112.
27. Keller S, Sauer I, Strauss H, Gast K, Dathe M, Bienert M. (2005). Membrane-mimetic nanocarriers formed by a dipalmitoylated cell-penetrating peptide. Angew Chem Int Ed Engl, 44, 5252-5255.
28. Kovacs JA. (1992). Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet, 340, 637-638.
29. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65-81.
30. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release, 49, 81-87.
31. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10, 317-325.
32. Lacassin F, Schaffo D, Perronne C, Longuet P, Leport C, Vilde JL. (1995). Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother, 39, 276-277.
33. Leupold E, Nikolenko H, Beyermann M, Dathe M. (2008). Insight into the role of HSPG in the cellular uptake of apolipoprotein E-derived peptide micelles and liposomes. Biochim Biophys Acta, 1778, 2781-2789.
34. Liu X, Chen C. (2005). Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Dev, 8, 505-512.
35. Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, et al. (1993). Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med, 329, 995-1000.
36. Luft BJ, Remington JS. (1992). Toxoplasmic encephalitis in AIDS. Clin Infect Dis, 15, 211-222.
37. Mahley RW. (1988). Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science, 240, 622-630.
38. Montoya JG, Liesenfeld O. (2004). Toxoplasmosis. Lancet, 363, 1965-1976.
39. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
40. Müller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by size reducing technique. Int J Pharm, 160, 229-237.
41. Müller RH, Benita S, Böhm BHL. (Eds.) (1998). Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart, Germany: Medpharm Verlag GmbH Scientific Publishers.
42. Müller, R.H., Lück, M., Kreuter, J., 1997. Arzneistoffträ gerpartikel für die gewebsspezifische Arzneistoffapplikation, German patent application No.197 45 950.1
43. Perriere N, Demeuse P, Garcia E, Regina A, Debray M, et al. (2005). Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrierspecific properties. J Neurochem, 93, 279-289.
44. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, et al. (1994). Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol, 37, 13-20.
45. Romand S, Pudney M, Derouin F. (1993). In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother, 37, 2371-2378.
46. Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, et al. (1993). Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis, 12, 853-856.
47. Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M. (2005). An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry, 44, 2021-2029.
48. Sauer I, Nikolenko H, Keller S, Abu Ajaj K, Bienert M, Dathe M. (2006). Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived peptide as a promising modification for stable anchorage in liposomal drug carriers. Biochim Biophys Acta, 1758, 552-561.
49. Scholer N, Krause K, Kayser O, Muller RH, Borner K, et al. (2001). Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother, 45, 1771-1779.
50. Shamenkov DA, Petrov VE, Alyautdin RN. (2006). Effects of apolipoproteins on dalargin transport across the blood-brain barrier. Bull Exp Biol Med, 142, 703-706.
51. Snyder EL, Dowdy SF. (2004). Cell penetrating peptides in drug delivery. Pharm Res, 21, 389-393.
52. Sordet F, Aumjaud Y, Fessi H, Derouin F. (1998). Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite, 5, 223-229.
53. Veszelka S, Pasztoi M, Farkas AE, Krizbai I, Ngo TK, et al. (2007). Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int, 50, 219-228.